Table 1.
Patient demographics, baseline characteristics, and characteristics of attacks that occurred up to 3 mo before patient screening
| Characteristic | Patients n = 12 | |
|---|---|---|
| Age, y, median (range) | 10.0 (7‐11) | |
| Sex, n (%) | Female | 7 (58.3) |
| Race, n (%) | White | 11 (91.7) |
| Mixed: Black, White | 1 (8.3) | |
| Body mass index, kg/m2, median (range) | 18.6 (13.1‐28.2) | |
| HAE type I, n (%) | 12 (100) | |
| Patients with first‐degree relative with HAE,a n (%) | 9 (75.0) | |
| Patients who received HAE therapy 9 mo before screening, n (%) | 8 (66.7) | |
| Attacks that occurred in 3 mo before screening | ||
| Number of attacks, median (range) | 5.5 (3‐48) | |
| Locations affected by attacks, n (%) | Upper airway | 3 (25.0) |
| Gastrointestinal tract or abdomen | 12 (100) | |
| Genitourinary | 2 (16.7) | |
| Facial | 7 (58.3) | |
| Extremity or peripheral | 10 (83.3) | |
| Average severity of attacks experienced by patient, n (%) | Moderate | 9 (75.0) |
| Severe | 3 (25.0) | |
| Average duration of attack, days, median (range) | 1.5 (1‐3) | |
| Patients needing acute treatment for HAE attack, n (%) | 11 (91.7) | |
HAE, hereditary angioedema.
Six patients had ≥1 sibling diagnosed with HAE.
a
Eight patients had a mother, and 1 had a father, diagnosed with HAE.